References

  1. Melander C, Joly D, Knebelmann B. Polykystose rénale autosomique dominante: la lumière au bout du tunnel? Néphrol ther. 2010;6 (4):226-31. PubMed | Google Scholar

  2. Burtey S, Berland Y. La Polykystose rénale. La Rev Prat. 2009 Jun 20;59(6):837-8. PubMed | Google Scholar

  3. Friedhelm Hildebrandt, Thomas Benzing, Nicholas Katsanis. Ciliopathies. N Engl J Med. 2011 Apr 21;364(16):1533-43. PubMed | Google Scholar

  4. Ul Haque A, Moatasim A. Adult Polycystic Kidney Disease: A Disorder of Connective Tissue? Int J Clin Exp Pathol. 2008 Jan 1;1(1):84-90. PubMed | Google Scholar

  5. Peters D, Sandkuijl L. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. 1992;97:128-39. PubMed | Google Scholar

  6. Daoust M, Reynolds D, Bichet D, Somlo S. Evidence of a third genetic locus for autosomal dominant polycystic kidney disease. Genomics. 1995 Feb 10;25(3):733-6. PubMed | Google Scholar

  7. Laleye A, awede B, Agboton B, Azonbakin S, Biaou O, Sagbo G, Adjagba M, Audrezet MP, Ferec C, Darboux R. Autosomal dominant polycystic kidney disease in university clinic of nephrology and haemodialysis of cotonou: clinical and genetical findings. Geneticcounseling. 2012;23(4):435-445. PubMed | Google Scholar

  8. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):820-9. PubMed | Google Scholar

  9. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18. PubMed | Google Scholar

  10. Zhou X, Fan LX, Sweeney Jr WE, Denu JM, Avner ED, Li X. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013 Jul;123(7):3084-98. PubMed | Google Scholar

  11. Pei Y, Magistroni R, Parfrey P, Coto E, Torra R, San Millan Jl et al. Unified ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20(1):205-212. PubMed | Google Scholar

  12. National-Kidney-Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J KidneyDis. 2002 Feb;39(2 Suppl 1):S1-266. PubMed | Google Scholar

  13. Gomez FP, Cosmesg P, Becerra CL, Romo TJ. Análisis clínico de una población con poliquistosis renal autosómica dominante. Nefrología. 2010;30 (1):87-94. PubMed | Google Scholar

  14. Peralta CA, Lin F, Shlipak Mg, Siscovick D, Lewis C, Jacobs D, Bibbins-Domingo K. Race differences in prevalence of chronic kidney disease among young adults using creatinine-based glomerular filtration rate-estimating equations. Nephrol Dial Transplant. 2010;25(12):3934-9. PubMed | Google Scholar

  15. Bourquia A. La maladie polykystique autosomique dominante au Maroc: Enquête multicentrique à propos de 308 familles. Néphrologie. 2002;23(2):93-6. PubMed | Google Scholar

  16. Torres E, Harris C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149-68. PubMed | Google Scholar

  17. Elhadj Fary Ka, Seck M, Niang A, Cisse M, Diouf B. Pattern of autosomal dominant polycistic kidney diseases in black africans. Saudi J Kidney Dis Transpl. 2010; 21(1): 81-6. PubMed | Google Scholar

  18. Reed B, Mcfann K, Kimberling W, Pei Y, Gabow P, Christopher K et al. Presence of de Novo Mutations in Autosomal Dominant Polycystic Kidney Disease Patients Without Family History. Am J Kidney Dis. 2008;52(6):1042-50. PubMed | Google Scholar

  19. Chijioke A, Aderibigbe A, Olusegun Olarenwaju T, Makusidi A, Oguntoyinbo AE. Prevalence and pattern of cystic kidney diseases in Ilorin, Nigeria. Saudi J Kidney Dis Transplant. 2010;21(6):1172-8. PubMed | Google Scholar

  20. Harris PC, Torres VE. Polycystickidney disease. Annu Rev Med. 2009;60:321-37. PubMed | Google Scholar

  21. Lespinasse J, Fourcade C, Schir F. Polycystic kidney diseases: molecular genetics and counseling. Néphrologie & Thérapeutique. 2006 Jul;2(3):120-6. PubMed | Google Scholar

  22. FONDATION PKD. http://pkdb.mayo.edu. www.pkdcure.org. (En ligne) 1982. (Citation : 05 Août 2011). PubMed | Google Scholar

  23. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2006 Jul;2(3):120-6. PubMed | Google Scholar

  24. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999;10:2426-39. PubMed | Google Scholar

  25. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal dominant polycystic kidney disease: results of a 7-years prospective randomized study. J Am Soc Nephrol. 2002;13:1733-9. PubMed | Google Scholar

  26. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003 Feb;63(2):678-85. PubMed | Google Scholar

  27. Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population based study. Am J Kidney Dis. 2011 Jun;57(6):856-62. PubMed | Google Scholar

  28. Schrier RW. Renal volume, renin-angiotensin- aldosterone system, hypertension and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20(9):1888-1893. PubMed | Google Scholar

  29. Hateboer N, Van Dijk Ma, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet. 1999;353(9147):103-7. PubMed | Google Scholar